"In this open-label, randomized, 90-day study"
ok, so this was never blinded to begin with, so no big deal. In the ufh study emis have had patients take both shots and the nasty tasting snac liquid. I guess the rules are all relaxed for the vitamins.
That's actually where I see all of this going at some point, selling out to NVS. There are too many potential applications for this thing for big pharma not to take advantage of it all. Personally, I was hoping for $80 or more :) Maybe in a couple of years, I'd be willing to wait a bit for that.
OK so how about a $10MM note written off plus $20MM up front, 20% royalties. Sandoz. Totally makes sense. Sandoz ads from B12 injections (soon to be wiped out) all over the internet. That's why they delayed the note! to see the results!
that would be a great match! hope they read the message board.That would make it easier to sell the whole company to NVS in a couple of years for a tidy profit! They could sell Victoza to Novo first and just pay us a special dividend, just to be greedy.
It did not make sense to me either. The PR sounds like the data was all in and being presented. Then as some type of after thought the PR mentions last patient data is not accounted for yet.
My understanding is in any blinded trial, all the data is avaialable until it is unblinded, but you just don't know which patients are active vs placebo, or in this case oral vs injection. But since all the patients acheived normalized levels, it isn't an issue. I suppose they could be generalizing the results and there may be some material difference in the results that is discovered after the results are unblinded, but I can't imagine the company would be stupid enough to go out on a limb?